Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Investigate Safety and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).

NCT05889273 is registered in ClinicalTrials.gov with MapLight Therapeutics as lead sponsor.

NCT NCT05889273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05889273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Investigate Safety and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).
Lead sponsor
MapLight Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 1, 2023
Completion date
December 31, 2027
Enrollment
120 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder